Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis | NEJM
New England Journal of Medicine
Original Article from The New England Journal of Medicine — Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Looking at the research on this new drug - dupilumab - for atopic dermatitis (for personal reasons). I have a question for my pharma friends. Is this how clinical trials work in pharma - several sponsor authors & data analysis by the sponsors too?